Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

In the ELEVATE-RR study, Calquence (acalabrutinib) matched Imbruvica (ibrutinib) when it came to keeping adults with previously treated, high-risk CLL alive without disease progression at a median ...

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.

Discover why JNJ's long-term buy rating is supported by its blue-chip status, profitability, and diverse revenue lines, ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...